What is the radiologist's role in variations of prostate cancer detection?

Radiologists' contributions to variations in detecting clinically significant prostate cancer are not significant, according to a new analysis.

JACR published the work online Oct. 13. For the study, experts reviewed the cases of more than 900 men with elevated PSA levels who had undergone multi-parametric prostate MRI (mpMRI) within six months (before or after) of biopsy and/or prostatectomy [1]. 

“Since their release, PI-RADS v2.0 and v2.1 have been the subject of numerous interreader variability studies showing moderate reproducibility in assessing prostate cancer lesions. Other studies have focused on in-practice variation between radiologists, with two concluding that cancer detection rates differ between radiologists, while another did not,” corresponding author Kristine Burk, MD, of Brigham and Women’s Hospital in Boston and colleagues explained. 

The authors added that prior studies focused on radiologist performance rather than patient outcomes, leaving the topic of variable diagnoses and what factors impact them—race, ethnicity, age, biopsy type, radiologist experience level, etc.—open for debate. 

To better understand what accounts for diagnosis variations within a multidisciplinary prostate cancer program, researchers gathered several years’ worth of data from an academic, National Cancer Institute-designated Comprehensive Cancer Center. This included 960 prostate MRIs from 928 men with an average age of 64. Clinically significant prostate cancer was detected in 59.8% of patients. 

The experts found that variations were not specific to individual clinicians. Radiologists’ interpretations did not contribute to the variations significantly, but rather the researchers found that PSA density, private insurance and unambiguous extra-prostatic extension on mpMRI were each independently associated with clinically significant prostate cancer. PI-RADS 3 assessment and race were not found to be contributing factors.

To learn more about the study’s findings, click here

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

Trimed Popup
Trimed Popup